App-Quantinova.ai

Long-term efficacy of secukinumab in the management of ankylosing spondylitis in clinical practice: real world data

Hoda Alkoky - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

An exploration of patients’ experiences of fatigue in axial spondyloarthitis

Doriana Xhaxho - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

The efficacy and tolerability of secukinumab in psoriatic arthritis and ankylosing spondylitis in NHS Tayside

Sam Cooper - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

secukinumab

Efficacy and safety outcomes in patients with axial spondyloarthritis treated with certolizumab pegol: results from the 48-week run-in part of a 96-week study (NCT02505542)

Robert Landewe - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

Certolizumab pegol

Analysis of referral patterns from a tertiary dermatology service to a tertiary rheumatology service in Guy’s and St Thomas’ hospital

Catherine D Hughes - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriasis

N/A

Patient reported effect of dietary modification on the symptoms of psoriatic arthritis: a social media survey

Olivia Ellis - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

N/A

Comparison of physician reported outcomes with patient reported outcomes in psoriatic arthritis patients

Ganesh Kasavkar - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Eosinophilic vasculitis in a traveller

Rohini Subramanya - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Eosinophilic granulomatosis with polyangiitis

N/A

Case review of tocilizumab use in giant cell arteritis and large vessel vasculitis in Belfast Health and Social Care Trust

Ursula Laverty - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Large vessel vasculitis

Tocilizumab

Patients with giant cell arteritis have a lower HbA1c compared to controls

Chetan Mukhtyar - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Giant cell arteritis

N/A

Clinical and laboratory associations with temporal artery biopsy result in suspected giant cell arteritis

Arabella Waller - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.

Talia Golan - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Olaparib

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.

Jean-Luc Van Laethem - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Pembrolizumab

Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

Andrew X. Zhu - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

Does non-TME surgery of rectal cancer compromise the chance of cure? Preliminary surgical salvage data from OPERA phase III randomized trial.

Arthur Sun Myint - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.

Eric Van Cutsem - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Tipiracil and trifluridine

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

Thierry Andre - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dostarlimab

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.

Kai-Keen Shiu - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Pembrolizumab

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort.

Hyun Cheol Chung - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Pembrolizumab

Wasat Mansoor - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Pembrolizumab

Filters

45280 Abstracts